World

COVID-19: Sanofi, GSK launch Phase III vaccine trial

France’s Sanofi and Britain’s GlaxoSmithKline launched a late-stage human trial for a recombinant COVID-19 vaccine candidate on Thursday which they hope to get approved by the end of 2021.

The study initiated by Sanofi and GSK is one of the first late stage trials that combines tests for boosters and variants, as drugmakers adapt their strategies to deal with an evolving coronavirus.

The two drugmakers, which earlier this month reported positive interim results, confirmed their double-blind, placebo-controlled, phase III study would include more than 35,000 adults in the United States, Asia, Africa, and Latin America.

Comments

Source
Gulf News

Related Articles

Back to top button